Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

Combination anti-Aβ treatment maximizes cognitive recovery and rebalances mTOR signaling in APP mice.

Chiang ACA, Fowler SW, Savjani RR, Hilsenbeck SG, Wallace CE, Cirrito JR, Das P, Jankowsky JL.

J Exp Med. 2018 Apr 6. pii: jem.20171484. doi: 10.1084/jem.20171484. [Epub ahead of print]

PMID:
29626114
2.

Microglial complement receptor 3 regulates brain Aβ levels through secreted proteolytic activity.

Czirr E, Castello NA, Mosher KI, Castellano JM, Hinkson IV, Lucin KM, Baeza-Raja B, Ryu JK, Li L, Farina SN, Belichenko NP, Longo FM, Akassoglou K, Britschgi M, Cirrito JR, Wyss-Coray T.

J Exp Med. 2017 Apr 3;214(4):1081-1092. doi: 10.1084/jem.20162011. Epub 2017 Mar 15.

3.

Astrocytic LRP1 Mediates Brain Aβ Clearance and Impacts Amyloid Deposition.

Liu CC, Hu J, Zhao N, Wang J, Wang N, Cirrito JR, Kanekiyo T, Holtzman DM, Bu G.

J Neurosci. 2017 Apr 12;37(15):4023-4031. doi: 10.1523/JNEUROSCI.3442-16.2017. Epub 2017 Mar 8.

4.

Bioactive Compound Screen for Pharmacological Enhancers of Apolipoprotein E in Primary Human Astrocytes.

Finan GM, Realubit R, Chung S, Lütjohann D, Wang N, Cirrito JR, Karan C, Kim TW.

Cell Chem Biol. 2016 Dec 22;23(12):1526-1538. doi: 10.1016/j.chembiol.2016.10.015. Epub 2016 Nov 23.

5.

Redundant Gs-coupled serotonin receptors regulate amyloid-β metabolism in vivo.

Fisher JR, Wallace CE, Tripoli DL, Sheline YI, Cirrito JR.

Mol Neurodegener. 2016 Jun 18;11(1):45. doi: 10.1186/s13024-016-0112-5.

6.

Bad Ac-etylated Tau.

Hettinger JC, Cirrito JR.

Neuron. 2016 Apr 20;90(2):205-6. doi: 10.1016/j.neuron.2016.04.008.

7.

TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques.

Wang Y, Ulland TK, Ulrich JD, Song W, Tzaferis JA, Hole JT, Yuan P, Mahan TE, Shi Y, Gilfillan S, Cella M, Grutzendler J, DeMattos RB, Cirrito JR, Holtzman DM, Colonna M.

J Exp Med. 2016 May 2;213(5):667-75. doi: 10.1084/jem.20151948. Epub 2016 Apr 18.

8.

Rapid in vivo measurement of β-amyloid reveals biphasic clearance kinetics in an Alzheimer's mouse model.

Yuede CM, Lee H, Restivo JL, Davis TA, Hettinger JC, Wallace CE, Young KL, Hayne MR, Bu G, Li CZ, Cirrito JR.

J Exp Med. 2016 May 2;213(5):677-85. doi: 10.1084/jem.20151428. Epub 2016 Apr 11.

9.

Neuronal heparan sulfates promote amyloid pathology by modulating brain amyloid-β clearance and aggregation in Alzheimer's disease.

Liu CC, Zhao N, Yamaguchi Y, Cirrito JR, Kanekiyo T, Holtzman DM, Bu G.

Sci Transl Med. 2016 Mar 30;8(332):332ra44. doi: 10.1126/scitranslmed.aad3650.

10.

A spectrum of exercise training reduces soluble Aβ in a dose-dependent manner in a mouse model of Alzheimer's disease.

Moore KM, Girens RE, Larson SK, Jones MR, Restivo JL, Holtzman DM, Cirrito JR, Yuede CM, Zimmerman SD, Timson BF.

Neurobiol Dis. 2016 Jan;85:218-224. doi: 10.1016/j.nbd.2015.11.004. Epub 2015 Nov 10.

PMID:
26563933
11.

microRNA-33 Regulates ApoE Lipidation and Amyloid-β Metabolism in the Brain.

Kim J, Yoon H, Horie T, Burchett JM, Restivo JL, Rotllan N, Ramírez CM, Verghese PB, Ihara M, Hoe HS, Esau C, Fernández-Hernando C, Holtzman DM, Cirrito JR, Ono K, Kim J.

J Neurosci. 2015 Nov 4;35(44):14717-26. doi: 10.1523/JNEUROSCI.2053-15.2015.

12.

Passive immunotherapy targeting amyloid-β reduces cerebral amyloid angiopathy and improves vascular reactivity.

Bales KR, O'Neill SM, Pozdnyakov N, Pan F, Caouette D, Pi Y, Wood KM, Volfson D, Cirrito JR, Han BH, Johnson AW, Zipfel GJ, Samad TA.

Brain. 2016 Feb;139(Pt 2):563-77. doi: 10.1093/brain/awv313. Epub 2015 Oct 22.

PMID:
26493635
13.

Neuronal-Targeted TFEB Accelerates Lysosomal Degradation of APP, Reducing Aβ Generation and Amyloid Plaque Pathogenesis.

Xiao Q, Yan P, Ma X, Liu H, Perez R, Zhu A, Gonzales E, Tripoli DL, Czerniewski L, Ballabio A, Cirrito JR, Diwan A, Lee JM.

J Neurosci. 2015 Sep 2;35(35):12137-51. doi: 10.1523/JNEUROSCI.0705-15.2015.

14.

Chronic optogenetic activation augments aβ pathology in a mouse model of Alzheimer disease.

Yamamoto K, Tanei ZI, Hashimoto T, Wakabayashi T, Okuno H, Naka Y, Yizhar O, Fenno LE, Fukayama M, Bito H, Cirrito JR, Holtzman DM, Deisseroth K, Iwatsubo T.

Cell Rep. 2015 May 12;11(6):859-865. doi: 10.1016/j.celrep.2015.04.017. Epub 2015 Apr 30.

15.

TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model.

Wang Y, Cella M, Mallinson K, Ulrich JD, Young KL, Robinette ML, Gilfillan S, Krishnan GM, Sudhakar S, Zinselmeyer BH, Holtzman DM, Cirrito JR, Colonna M.

Cell. 2015 Mar 12;160(6):1061-71. doi: 10.1016/j.cell.2015.01.049. Epub 2015 Feb 26.

16.

Contribution of reactive oxygen species to cerebral amyloid angiopathy, vasomotor dysfunction, and microhemorrhage in aged Tg2576 mice.

Han BH, Zhou ML, Johnson AW, Singh I, Liao F, Vellimana AK, Nelson JW, Milner E, Cirrito JR, Basak J, Yoo M, Dietrich HH, Holtzman DM, Zipfel GJ.

Proc Natl Acad Sci U S A. 2015 Feb 24;112(8):E881-90. doi: 10.1073/pnas.1414930112. Epub 2015 Feb 9.

17.

Reply to comment on "An antidepressant decreases CSF Aβ production in healthy individuals and in transgenic AD mice".

Sheline YI, West T, Yarasheski K, Jasielec MS, Hettinger JC, Tripoli DL, Xiong C, Frederiksen C, Grzelak MV, Bateman RJ, Morris JC, Lee JM, Cirrito JR.

Sci Transl Med. 2014 Dec 24;6(268):268lr4. doi: 10.1126/scitranslmed.3010609. No abstract available.

18.

Potential role of orexin and sleep modulation in the pathogenesis of Alzheimer's disease.

Roh JH, Jiang H, Finn MB, Stewart FR, Mahan TE, Cirrito JR, Heda A, Snider BJ, Li M, Yanagisawa M, de Lecea L, Holtzman DM.

J Exp Med. 2014 Dec 15;211(13):2487-96. doi: 10.1084/jem.20141788. Epub 2014 Nov 24. Erratum in: J Exp Med. 2015 Jan 12;212(1):121.

19.

Intravenously injected human apolipoprotein A-I rapidly enters the central nervous system via the choroid plexus.

Stukas S, Robert J, Lee M, Kulic I, Carr M, Tourigny K, Fan J, Namjoshi D, Lemke K, DeValle N, Chan J, Wilson T, Wilkinson A, Chapanian R, Kizhakkedathu JN, Cirrito JR, Oda MN, Wellington CL.

J Am Heart Assoc. 2014 Nov 12;3(6):e001156. doi: 10.1161/JAHA.114.001156.

20.

Enhancing astrocytic lysosome biogenesis facilitates Aβ clearance and attenuates amyloid plaque pathogenesis.

Xiao Q, Yan P, Ma X, Liu H, Perez R, Zhu A, Gonzales E, Burchett JM, Schuler DR, Cirrito JR, Diwan A, Lee JM.

J Neurosci. 2014 Jul 16;34(29):9607-20. doi: 10.1523/JNEUROSCI.3788-13.2014.

21.

Characterization of a brain permeant fluorescent molecule and visualization of Aβ parenchymal plaques, using real-time multiphoton imaging in transgenic mice.

Sundaram GS, Garai K, Rath NP, Yan P, Cirrito JR, Cairns NJ, Lee JM, Sharma V.

Org Lett. 2014 Jul 18;16(14):3640-3. doi: 10.1021/ol501264q. Epub 2014 Jul 8.

22.

Genetic modulation of soluble Aβ rescues cognitive and synaptic impairment in a mouse model of Alzheimer's disease.

Fowler SW, Chiang AC, Savjani RR, Larson ME, Sherman MA, Schuler DR, Cirrito JR, Lesné SE, Jankowsky JL.

J Neurosci. 2014 Jun 4;34(23):7871-85. doi: 10.1523/JNEUROSCI.0572-14.2014. Erratum in: J Neurosci. 2014 Dec 10;34(50):16917.

23.

An antidepressant decreases CSF Aβ production in healthy individuals and in transgenic AD mice.

Sheline YI, West T, Yarasheski K, Swarm R, Jasielec MS, Fisher JR, Ficker WD, Yan P, Xiong C, Frederiksen C, Grzelak MV, Chott R, Bateman RJ, Morris JC, Mintun MA, Lee JM, Cirrito JR.

Sci Transl Med. 2014 May 14;6(236):236re4. doi: 10.1126/scitranslmed.3008169.

24.

Genetic suppression of transgenic APP rescues Hypersynchronous network activity in a mouse model of Alzeimer's disease.

Born HA, Kim JY, Savjani RR, Das P, Dabaghian YA, Guo Q, Yoo JW, Schuler DR, Cirrito JR, Zheng H, Golde TE, Noebels JL, Jankowsky JL.

J Neurosci. 2014 Mar 12;34(11):3826-40. doi: 10.1523/JNEUROSCI.5171-13.2014.

25.

Neuronal activity regulates extracellular tau in vivo.

Yamada K, Holth JK, Liao F, Stewart FR, Mahan TE, Jiang H, Cirrito JR, Patel TK, Hochgräfe K, Mandelkow EM, Holtzman DM.

J Exp Med. 2014 Mar 10;211(3):387-93. doi: 10.1084/jem.20131685. Epub 2014 Feb 17.

26.

Neuronal clearance of amyloid-β by endocytic receptor LRP1.

Kanekiyo T, Cirrito JR, Liu CC, Shinohara M, Li J, Schuler DR, Shinohara M, Holtzman DM, Bu G.

J Neurosci. 2013 Dec 4;33(49):19276-83. doi: 10.1523/JNEUROSCI.3487-13.2013.

27.

Increased efflux of amyloid-β peptides through the blood-brain barrier by muscarinic acetylcholine receptor inhibition reduces pathological phenotypes in mouse models of brain amyloidosis.

Paganetti P, Antoniello K, Devraj K, Toni N, Kieran D, Madani R, Pihlgren M, Adolfsson O, Froestl W, Schrattenholz A, Liebner S, Havas D, Windisch M, Cirrito JR, Pfeifer A, Muhs A.

J Alzheimers Dis. 2014;38(4):767-86. doi: 10.3233/JAD-131091.

PMID:
24072071
28.

Antisense reduction of tau in adult mice protects against seizures.

DeVos SL, Goncharoff DK, Chen G, Kebodeaux CS, Yamada K, Stewart FR, Schuler DR, Maloney SE, Wozniak DF, Rigo F, Bennett CF, Cirrito JR, Holtzman DM, Miller TM.

J Neurosci. 2013 Jul 31;33(31):12887-97. doi: 10.1523/JNEUROSCI.2107-13.2013.

29.

Response to comments on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models".

Landreth GE, Cramer PE, Lakner MM, Cirrito JR, Wesson DW, Brunden KR, Wilson DA.

Science. 2013 May 24;340(6135):924-g. doi: 10.1126/science.1234114.

30.

In vivo measurement of apolipoprotein E from the brain interstitial fluid using microdialysis.

Ulrich JD, Burchett JM, Restivo JL, Schuler DR, Verghese PB, Mahan TE, Landreth GE, Castellano JM, Jiang H, Cirrito JR, Holtzman DM.

Mol Neurodegener. 2013 Apr 19;8:13. doi: 10.1186/1750-1326-8-13.

31.

Amyloid-β oligomerization in Alzheimer dementia versus high-pathology controls.

Esparza TJ, Zhao H, Cirrito JR, Cairns NJ, Bateman RJ, Holtzman DM, Brody DL.

Ann Neurol. 2013 Jan;73(1):104-19. doi: 10.1002/ana.23748. Epub 2012 Dec 7.

32.

Attenuating astrocyte activation accelerates plaque pathogenesis in APP/PS1 mice.

Kraft AW, Hu X, Yoon H, Yan P, Xiao Q, Wang Y, Gil SC, Brown J, Wilhelmsson U, Restivo JL, Cirrito JR, Holtzman DM, Kim J, Pekny M, Lee JM.

FASEB J. 2013 Jan;27(1):187-98. doi: 10.1096/fj.12-208660. Epub 2012 Oct 4.

33.

Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model.

Sanchez PE, Zhu L, Verret L, Vossel KA, Orr AG, Cirrito JR, Devidze N, Ho K, Yu GQ, Palop JJ, Mucke L.

Proc Natl Acad Sci U S A. 2012 Oct 16;109(42):E2895-903. doi: 10.1073/pnas.1121081109. Epub 2012 Aug 6.

34.

Emergence of a seizure phenotype in aged apolipoprotein epsilon 4 targeted replacement mice.

Hunter JM, Cirrito JR, Restivo JL, Kinley RD, Sullivan PM, Holtzman DM, Koger D, Delong C, Lin S, Zhao L, Liu F, Bales K, Paul SM.

Brain Res. 2012 Jul 27;1467:120-32. doi: 10.1016/j.brainres.2012.05.048. Epub 2012 Jun 5.

PMID:
22682924
35.

Role of phosphatidylinositol clathrin assembly lymphoid-myeloid leukemia (PICALM) in intracellular amyloid precursor protein (APP) processing and amyloid plaque pathogenesis.

Xiao Q, Gil SC, Yan P, Wang Y, Han S, Gonzales E, Perez R, Cirrito JR, Lee JM.

J Biol Chem. 2012 Jun 15;287(25):21279-89. doi: 10.1074/jbc.M111.338376. Epub 2012 Apr 26.

36.

Bidirectional relationship between functional connectivity and amyloid-β deposition in mouse brain.

Bero AW, Bauer AQ, Stewart FR, White BR, Cirrito JR, Raichle ME, Culver JP, Holtzman DM.

J Neurosci. 2012 Mar 28;32(13):4334-40. doi: 10.1523/JNEUROSCI.5845-11.2012.

37.

Microbiosensor for Alzheimer's disease diagnostics: detection of amyloid beta biomarkers.

Prabhulkar S, Piatyszek R, Cirrito JR, Wu ZZ, Li CZ.

J Neurochem. 2012 Jul;122(2):374-81. doi: 10.1111/j.1471-4159.2012.07709.x. Epub 2012 Apr 23.

38.

ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models.

Cramer PE, Cirrito JR, Wesson DW, Lee CY, Karlo JC, Zinn AE, Casali BT, Restivo JL, Goebel WD, James MJ, Brunden KR, Wilson DA, Landreth GE.

Science. 2012 Mar 23;335(6075):1503-6. doi: 10.1126/science.1217697. Epub 2012 Feb 9.

39.

Dynamic analysis of amyloid β-protein in behaving mice reveals opposing changes in ISF versus parenchymal Aβ during age-related plaque formation.

Hong S, Quintero-Monzon O, Ostaszewski BL, Podlisny DR, Cavanaugh WT, Yang T, Holtzman DM, Cirrito JR, Selkoe DJ.

J Neurosci. 2011 Nov 2;31(44):15861-9. doi: 10.1523/JNEUROSCI.3272-11.2011.

40.

In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice.

Yamada K, Cirrito JR, Stewart FR, Jiang H, Finn MB, Holmes BB, Binder LI, Mandelkow EM, Diamond MI, Lee VM, Holtzman DM.

J Neurosci. 2011 Sep 14;31(37):13110-7. doi: 10.1523/JNEUROSCI.2569-11.2011.

41.

Serotonin signaling is associated with lower amyloid-β levels and plaques in transgenic mice and humans.

Cirrito JR, Disabato BM, Restivo JL, Verges DK, Goebel WD, Sathyan A, Hayreh D, D'Angelo G, Benzinger T, Yoon H, Kim J, Morris JC, Mintun MA, Sheline YI.

Proc Natl Acad Sci U S A. 2011 Sep 6;108(36):14968-73. doi: 10.1073/pnas.1107411108. Epub 2011 Aug 22.

42.

Opposing synaptic regulation of amyloid-β metabolism by NMDA receptors in vivo.

Verges DK, Restivo JL, Goebel WD, Holtzman DM, Cirrito JR.

J Neurosci. 2011 Aug 3;31(31):11328-37. doi: 10.1523/JNEUROSCI.0607-11.2011.

43.

Anti-Amyloid-β Single-Chain Antibody Brain Delivery Via AAV Reduces Amyloid Load But May Increase Cerebral Hemorrhages in an Alzheimer's Disease Mouse Model.

Kou J, Kim H, Pattanayak A, Song M, Lim JE, Taguchi H, Paul S, Cirrito JR, Ponnazhagan S, Fukuchi K.

J Alzheimers Dis. 2011;27(1):23-38. doi: 10.3233/JAD-2011-110230.

44.

Neuronal activity regulates the regional vulnerability to amyloid-β deposition.

Bero AW, Yan P, Roh JH, Cirrito JR, Stewart FR, Raichle ME, Lee JM, Holtzman DM.

Nat Neurosci. 2011 Jun;14(6):750-6. doi: 10.1038/nn.2801. Epub 2011 May 1.

45.

Beta-secretase inhibitor GRL-8234 rescues age-related cognitive decline in APP transgenic mice.

Chang WP, Huang X, Downs D, Cirrito JR, Koelsch G, Holtzman DM, Ghosh AK, Tang J.

FASEB J. 2011 Feb;25(2):775-84. doi: 10.1096/fj.10-167213. Epub 2010 Nov 8.

46.

Traumatic brain injury reduces soluble extracellular amyloid-β in mice: a methodologically novel combined microdialysis-controlled cortical impact study.

Schwetye KE, Cirrito JR, Esparza TJ, Mac Donald CL, Holtzman DM, Brody DL.

Neurobiol Dis. 2010 Dec;40(3):555-64. doi: 10.1016/j.nbd.2010.06.018. Epub 2010 Aug 1.

47.

ApoE mimetic peptide decreases Abeta production in vitro and in vivo.

Minami SS, Cordova A, Cirrito JR, Tesoriero JA, Babus LW, Davis GC, Dakshanamurthy S, Turner RS, Pak DTs, Rebeck GW, Paige M, Hoe HS.

Mol Neurodegener. 2010 Apr 20;5:16. doi: 10.1186/1750-1326-5-16.

48.

Acute dosing of latrepirdine (Dimebon), a possible Alzheimer therapeutic, elevates extracellular amyloid-beta levels in vitro and in vivo.

Steele JW, Kim SH, Cirrito JR, Verges DK, Restivo JL, Westaway D, Fraser P, Hyslop PS, Sano M, Bezprozvanny I, Ehrlich ME, Holtzman DM, Gandy S.

Mol Neurodegener. 2009 Dec 17;4:51. doi: 10.1186/1750-1326-4-51.

49.

Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle.

Kang JE, Lim MM, Bateman RJ, Lee JJ, Smyth LP, Cirrito JR, Fujiki N, Nishino S, Holtzman DM.

Science. 2009 Nov 13;326(5955):1005-7. doi: 10.1126/science.1180962. Epub 2009 Sep 24.

50.

Characterizing the appearance and growth of amyloid plaques in APP/PS1 mice.

Yan P, Bero AW, Cirrito JR, Xiao Q, Hu X, Wang Y, Gonzales E, Holtzman DM, Lee JM.

J Neurosci. 2009 Aug 26;29(34):10706-14. doi: 10.1523/JNEUROSCI.2637-09.2009.

Supplemental Content

Loading ...
Support Center